List of seasonal influenza vaccines
Seasonal influenza vaccine brands include Fluzone/Fluzone Quadrivalent[1] and Vaxigrip/VaxigripTetra,[2] Influvac and Optaflu.
Fluenz, FluMist and their quadrivalent formulations are nasal attenuated vaccines by AstraZeneca.
Fluarix, Flulaval and their quadrivalent formulations are split virus inactivated vaccines by GlaxoSmithKline.[7]
Influvac and its quadrivalent formulation are surface antigen subunit vaccines marketed by Mylan.
They contain inactivated purified surface fragments (subunits) from the three different strains of the influenza virus (A/H1N1, A/H3N2, and Influenza B virus) that are selected and distributed by the World Health Organization, on the basis of their latest recommendations. Previously, they were produced and marketed by Abbott Laboratories[9]
In February 2010, Abbott acquired the vaccines subunit from Solvay Pharmaceuticals included in its $6.2 billion purchase[10] and the subunit influenza vaccine — Influvac has been commercially available on the market since the early nineteen-eighties.[9] With the acquisition of Solvay, Abbott retained access to the Eastern European, Middle Eastern & Latin American markets. Approximately $850 million of sales revenue from vaccines was reported by Solvay Pharmaceuticals in 2009.[10]
In February 2015, Mylan Laboratories completed the deal with Abbott to purchase Abbott's generic drugs business in developed markets, which includes Influvac.[11][12]
In some countries, Influvac is marketed by Viatris after Upjohn merged with Mylan to create Viatris.[13][14]
Novartis[edit]
Optaflu is a trivalent surface antigen inactivated vaccine prepared in cell cultures manufactured by Novartis.
In April 2007, Novartis received a positive opinion supporting European Union approval of Optaflu. It is the first influenza vaccine made in a mammalian cell line, rather than chicken eggs.[15] The plan was to manufacture the vaccine in Holly Springs, North Carolina. The United States government provided $500 million in construction costs and guaranteed vaccine purchases.[16]
Novartis' flu vaccine unit was sold to CSL Limited in 2014, and was placed under CSL subsidiary, bioCSL (Seqirus).[17]
bioCSL as marketing authorization holder decided to discontinue the usage of Optaflu brand in 2017 due to commercial reasons[18]
Vaxigrip Tetra and Fluquadri are quadrivalent split virus inactivated vaccines by Sanofi-Aventis.
Afluria and its quadrivalent formulation are a split virus inactivated vaccines. Fluad and its quadrivalent formulations are adjuvanted surface antigen inactivated vaccines. Flucelvax and its quadrivalent formulations are surface antigen inactivated vaccines prepared in cell cultures.
Novartis developed the first influenza vaccine, which did not need to be grown in chicken eggs, a cell-based vaccine.[30]
In 2014, CSL Limited obtained Novartis' flu vaccine unit, and transferred it to CSL Subsidiary, bioCSL, named Seqirus.[17]
The following are list of bioCSL flu vaccine brands:[31]